Natixis Advisors LLC Purchases 53,625 Shares of Haleon plc (NYSE:HLN)

Natixis Advisors LLC boosted its position in shares of Haleon plc (NYSE:HLN - Free Report) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,527,392 shares of the company's stock after buying an additional 53,625 shares during the period. Natixis Advisors LLC's holdings in Haleon were worth $14,571,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. First Eagle Investment Management LLC grew its stake in Haleon by 4.7% during the fourth quarter. First Eagle Investment Management LLC now owns 2,104,289 shares of the company's stock worth $20,075,000 after buying an additional 93,553 shares in the last quarter. Atala Financial Inc acquired a new stake in shares of Haleon in the 4th quarter valued at approximately $104,000. EverSource Wealth Advisors LLC boosted its stake in shares of Haleon by 23.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 14,601 shares of the company's stock valued at $139,000 after purchasing an additional 2,747 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in shares of Haleon by 2.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 85,690 shares of the company's stock valued at $814,000 after purchasing an additional 2,101 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in shares of Haleon by 3.4% in the 4th quarter. HighTower Advisors LLC now owns 362,685 shares of the company's stock valued at $3,460,000 after purchasing an additional 11,890 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Haleon Trading Down 1.0 %

NYSE HLN traded down $0.11 during trading hours on Friday, reaching $10.29. The company's stock had a trading volume of 9,109,232 shares, compared to its average volume of 6,483,522. The firm has a fifty day simple moving average of $9.84 and a 200-day simple moving average of $9.88. The stock has a market cap of $46.56 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon plc has a 52 week low of $7.99 and a 52 week high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Equities analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This is a positive change from Haleon's previous -- dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon's dividend payout ratio (DPR) is presently 58.97%.

Analyst Ratings Changes

HLN has been the topic of a number of research analyst reports. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Finally, Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.